Antiparasitic Drugs in Oncology: 2026 Comprehensive Review (7 Drugs, Multiple Cancers)
A 2026 review from Hamad Medical Corporation and Qatar University synthesizes the anticancer evidence for seven antiparasitic drugs — ivermectin, mebendazole, niclosamide, albendazole, artesunate, flubendazole, and pyrvinium pamoate — across multiple cancer types.
By Sanare Lab · June 30, 2026 · 7 min read
Key Takeaway
A comprehensive 2026 review published in the European Journal of Medicinal Chemistry by researchers at Hamad Medical Corporation (Qatar) and Qatar University synthesizes the anticancer evidence for seven antiparasitic drugs — ivermectin, mebendazole, niclosamide, albendazole, artesunate, flubendazole, and pyrvinium pamoate — across multiple cancer types. The review identifies microtubule disruption, apoptosis induction, and oncogenic pathway inhibition as the primary shared mechanisms, while noting that clinical translation remains the field's central challenge.
A 2026 review in the European Journal of Medicinal Chemistry by researchers at Hamad Medical Corporation in Qatar and Qatar University looked at evidence for seven antiparasitic drugs as possible cancer treatments: ivermectin, mebendazole, niclosamide, albendazole, artesunate, flubendazole, and pyrvinium pamoate. It covered many cancer types and found shared possible actions, including damaging microtubules (cell support structures), triggering apoptosis (programmed cell death), and blocking oncogenic pathways (cancer-driving signals). The review stresses that turning this research into clinical cancer treatment remains the main challenge.
The concept of repurposing established antiparasitic drugs for cancer treatment has moved from a fringe hypothesis to a legitimate area of oncology research over the past decade. A major new review article published in the European Journal of Medicinal Chemistry (May 2026, print October 2026) by Al-Zoubi et al. from Hamad Medical Corporation and Qatar University provides one of the most comprehensive summaries to date of where this field stands — covering seven drugs, dozens of cancer types, and the key obstacles to clinical translation.
For patients and caregivers researching repurposed antiparasitic drugs, this review is valuable because it synthesizes evidence across the entire drug class rather than focusing on a single compound. It also provides an honest assessment of what the evidence does and does not support.
Here is a structured summary of the review's key findings, organized by drug and mechanism.
Table of Contents
- Review Overview
- Shared Anticancer Mechanisms
- Drug-by-Drug Evidence Summary
- Clinical Translation Challenges
- What This Means for Patients
- FAQ
- Shop Sanare Lab
- References
Review Overview
The review was authored by Al-Zoubi RM and colleagues from Hamad Medical Corporation (Doha, Qatar), Qatar University, and Jordan University of Science and Technology. It was published online May 25, 2026 in the European Journal of Medicinal Chemistry, a high-impact peer-reviewed journal (Impact Factor ~6.7).
| Parameter | Details |
|---|---|
| Article type | Comprehensive review |
| Drugs covered | Ivermectin, mebendazole, niclosamide, albendazole, artesunate, flubendazole, pyrvinium pamoate |
| Institution | Hamad Medical Corporation + Qatar University, Doha, Qatar |
| Journal | European Journal of Medicinal Chemistry, Vol. 316, 2026 |
| Published online | May 25, 2026. DOI: 10.1016/j.ejmech.2026.118987. PMID: 42217373 |
Shared Anticancer Mechanisms Across the Drug Class
One of the review's most useful contributions is identifying the mechanisms that multiple antiparasitic drugs share when acting against cancer cells. These shared pathways explain why the entire drug class has attracted oncology research interest:
| Mechanism | Drugs Involved | Effect on Cancer |
|---|---|---|
| Microtubule disruption | Mebendazole, albendazole, flubendazole, fenbendazole | Prevents cell division; G2/M arrest |
| Apoptosis induction | All seven drugs | Triggers programmed cancer cell death |
| Wnt/beta-catenin inhibition | Niclosamide, mebendazole, pyrvinium pamoate | Blocks cancer stem cell renewal |
| PI3K/Akt/mTOR inhibition | Ivermectin, niclosamide, artesunate | Suppresses tumor growth signaling |
| Hedgehog pathway inhibition | Ivermectin, mebendazole | Blocks developmental pathway hijacked by tumors |
| P-glycoprotein inhibition | Ivermectin | Reverses multidrug resistance |
| ROS induction | Artesunate, niclosamide | Oxidative stress kills cancer cells |
| Cancer stem cell targeting | Niclosamide, mebendazole, ivermectin | Targets treatment-resistant tumor-initiating cells |
Drug-by-Drug Evidence Summary
The review covers each drug's evidence base across cancer types. Here is a condensed summary of the key points for the drugs most relevant to this blog's readership:
Ivermectin: The review highlights ivermectin's activity against breast, ovarian, and colorectal cancer models through P-glycoprotein inhibition, chloride channel activation, and oncogenic signaling suppression. The authors note that ivermectin's ability to reverse multidrug resistance is particularly clinically relevant, as resistance to standard chemotherapy is a major cause of treatment failure.
Mebendazole: Described as exerting anticancer effects "primarily through inhibition of tubulin polymerization, mirroring mechanisms of conventional taxane and vinca alkaloid chemotherapeutics." The review also highlights mebendazole's anti-angiogenic properties (blocking new blood vessel formation that tumors need to grow) and immunostimulatory effects. The authors note that mebendazole has demonstrated activity in glioblastoma, colorectal, and lung cancer models.
Niclosamide: Identified as a STAT3 and Wnt pathway inhibitor with activity against colon, prostate, and breast cancer models. The review notes that niclosamide has entered early clinical trials for prostate cancer.
Artesunate: The antimalarial drug artesunate is highlighted for its reactive oxygen species (ROS)-mediated cancer cell killing. The review notes early clinical evidence in colorectal cancer.
Flubendazole: Noted for its potent in vitro activity but poor oral bioavailability, with nanoformulation research ongoing to overcome this barrier.
Pyrvinium pamoate: An older antiparasitic drug that blocks the Wnt pathway and has shown activity against cancer stem cells in preclinical models.
Clinical Translation: The Central Challenge
The review is candid about the gap between preclinical promise and clinical reality. The authors identify several key obstacles to translating antiparasitic drugs into approved cancer treatments:
- Bioavailability: Many benzimidazole drugs (mebendazole, fenbendazole, flubendazole) have poor and variable oral absorption, making it difficult to achieve consistent therapeutic concentrations in tumor tissue.
- Lack of randomized controlled trials: Most evidence comes from in vitro and animal studies. The few human studies are small, observational, or early-phase trials without control groups.
- Funding challenges: Because these drugs are off-patent, pharmaceutical companies have little financial incentive to fund large clinical trials. Academic and government funding is the primary driver of clinical research.
- Optimal dosing unknown: The doses used in preclinical studies often cannot be directly translated to humans due to differences in pharmacokinetics and toxicity profiles.
- Regulatory pathway: Repurposed drugs face a complex regulatory pathway for new cancer indications, even when safety data already exists from their original approved use.
What This Means for Patients Researching These Drugs
This review reinforces several key points for patients and caregivers who are researching antiparasitic drugs as potential cancer adjuncts:
- The preclinical evidence base for this drug class is substantial and growing. Multiple independent research groups across multiple countries have confirmed anticancer activity in laboratory models.
- The clinical evidence remains limited. No antiparasitic drug has been approved as a cancer treatment, and the evidence from human studies is preliminary.
- The drugs in this class are not interchangeable. Each has a distinct pharmacological profile, bioavailability, safety record, and evidence base for specific cancer types.
- Combination strategies — pairing antiparasitic drugs with standard chemotherapy or with each other — are an active area of research and may be where the most clinical benefit ultimately lies.
- Patients considering these drugs should discuss them with their oncologist, particularly regarding potential drug interactions with their current treatment regimen.
For background, see our guide to the Joe Tippens protocol.
We cover this in more depth in our article on the Care Oncology (COC) protocol.
For the fuller picture, read our deep dive into the ISOM metabolic protocol.
You can map out a weight-based schedule using our dosage calculator.
Frequently Asked Questions
Which antiparasitic drug has the strongest evidence for cancer treatment?
Based on the volume of research and early clinical data, mebendazole and ivermectin have the most developed evidence bases. Mebendazole has been studied in clinical trials for glioblastoma and colorectal cancer. Ivermectin has been investigated in multiple early-phase trials. However, "strongest evidence" is relative — none of these drugs has completed Phase III trials demonstrating clinical benefit in cancer patients, so all remain investigational for oncology use.
Is niclosamide available for cancer patients?
Niclosamide is an FDA-approved antiparasitic drug for tapeworm infections, so it is available by prescription. However, it is not approved for cancer treatment, and its use in oncology is investigational. Early clinical trials have been conducted for prostate cancer. Niclosamide has very poor oral bioavailability, which has been a major obstacle to its development as a cancer drug, and researchers are working on reformulations to improve absorption.
What is the Wnt/beta-catenin pathway and why does it matter in cancer?
The Wnt/beta-catenin signaling pathway is a fundamental developmental pathway that regulates cell growth, differentiation, and stem cell renewal. In many cancers — particularly colorectal cancer, where Wnt mutations are found in ~90% of tumors — this pathway is abnormally activated, driving uncontrolled cell proliferation and maintaining cancer stem cell populations. Drugs that inhibit Wnt signaling (niclosamide, mebendazole, pyrvinium pamoate) are of interest because they may target the root cause of tumor growth and treatment resistance.
Why don't pharmaceutical companies fund trials of these repurposed drugs?
The primary reason is financial: these drugs are off-patent, meaning any company that funds a successful trial cannot recoup its investment through exclusive sales rights. A competitor could immediately sell the same drug for the new indication. This creates a market failure where drugs with genuine therapeutic potential go unstudied because there is no profit motive. Academic medical centers, government agencies (like the NCI), and patient advocacy organizations are the primary funders of repurposed drug research in oncology.
What is artesunate and how does it fight cancer?
Artesunate is a derivative of artemisinin, the active compound in the antimalarial herb Artemisia annua (sweet wormwood). It kills cancer cells primarily by generating reactive oxygen species (ROS) — highly reactive molecules that damage cancer cell membranes, DNA, and mitochondria. Cancer cells are often more vulnerable to oxidative stress than normal cells because they already operate under higher baseline oxidative conditions. Artesunate has shown activity in colorectal, breast, and lung cancer models, and early clinical trials have been conducted in colorectal cancer.
Shop Sanare Lab
Lab-tested products referenced in the research above. Links are provided for convenience — always review the label and consult a professional before use.
180 capsules — 99% purity, laboratory tested
100 tablets — pharmaceutical-grade
Disclaimer: Links are informational and for convenience. This site does not provide medical advice and does not endorse any specific vendor. Always verify product quality, labeling, and consult a licensed professional for health decisions.
References
- Al-Zoubi RM, Farhan A, Hanbali B, et al. Antiparasitic agents in oncology: Innovative mechanisms, emerging evidence and clinical potential in cancer treatment. Eur J Med Chem. 2026;316:118987. doi:10.1016/j.ejmech.2026.118987. PMID: 42217373. PubMed
- Pantziarka P, Bouche G, Meheus L, et al. Repurposing drugs in oncology (ReDO) — mebendazole as an anti-cancer agent. Ecancermedicalscience. 2014;8:443. doi:10.3332/ecancer.2014.443.
- Juarez M, Schcolnik-Cabrera A, Dueñas-Gonzalez A. The multitargeted drug ivermectin: from an antiparasitic agent to a repositioned cancer drug. Am J Cancer Res. 2018;8(2):317-331. PMID: 29511601.
Medical Disclaimer
This article is for educational and informational purposes only. It is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
Sanare Lab
Science-based health education team reviewing published research on repurposed drugs, integrative oncology, and evidence-based protocols.